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Objectives: To estimate the cumulative incidence and hospital cost for venous and 
pulmonary thromboembolic events in a real world setting in France. MethOds: We 
conducted a retrospective analysis of the EGB database, a 1/97th random sample of 
the whole National health insurance database records linked to hospitalizations. 
All patients hospitalized in 2010 and 2011 with a diagnosis of deep vein thrombo-
sis (DVT) or pulmonary embolism (PE) were included. Inpatients were identified 
through principal diagnosis of hospitalization stay. Outpatients with a DVT were 
identified by 1) an echo Doppler exam, 2) preceded or followed by a low molecular 
weight heparin or fondaparinux delivery (+/-7 days), and 3) a subsequent Vitamin K 
antagonists delivery (0 to 7 days). Incidences and annual hospital cost of DVT and PE 
were estimated and extrapolated to the overall French population, and cumulative 
proportions of recurrences were calculated. Results: For 2011, the estimated crude 
incidences were 141/100,000 (91,650 patients) for DVT, and 79.4/100,000 for PE (51,610 
patients in France). Mean age of patients was 67.0+/-17.2 years for PE and 64.1+/-17.7 
years for DVT. A majority of patients were females (57% in both groups). After index 
event (PE/DVT), the cumulative proportions of venous thromboembolic recurrences 
were 2.6% at 1 month, 3.7% at 3 months, 5.1% at 6 months and 6.7% at 12 months. 
The cumulative proportions of death after a PE and a DVT first event were 0.2% at 1 
month, 1.1% at 3 months, 2.6% at 6 months and 6.2% at 12 months. Annual hospital 
cost of venous and pulmonary thromboembolic events was estimated at 712 million 
€ (362 million € for DVT and 350 million € for PE). cOnclusiOns: In 2011, around 
143,000 patients suffered from venous and pulmonary thromboembolic events in 
France. Hospitalized events accounted for an important burden in France.
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Objectives: Non-adherence to blood pressure medications is common, present 
in 30-50% of patients, and known to be associated with an increased risk for major 
cardiovascular events and increased health care costs. Prior research suggests 
that impaired cognitive function is associated with medication non-adherence. 
Our aim was to determine if easily administered measures of cognitive function 
can be used to identify hypertensive patients at increased risk of medication non-
adherence. MethOds: A convenience sample of 101 primary care patients (n= 101) 
with uncontrolled hypertension was enrolled from two hospital-based clinics in 
ethnically diverse communities of New York City. Patients with overt dementia 
as noted by their primary care doctors were ineligible. Subjects completed three 
brief cognitive tests (≤ 5 minutes to complete each one): Trail Making Test-A, Trail 
Making Test-B, and the Symbol Digit Modalities Test. The primary outcome was 
adherence based on percentage of doses taken as prescribed, measured by a 4-com-
partment electronic pillbox (MedSignals). Multivariable logistic regression was used 
to determine if impaired cognitive function was associated with poor adherence 
after adjusting for age, gender, ethnicity, education, and total blood pressure medi-
cations. Results: Patients who were classified as impaired when screened by 
Trail Making Test-B had a three-fold (OR= 2.91,95% CI, 1.02-8.35) increased likeli-
hood of non-adherence compared with those who were not impaired, adjusting 
for age, education, gender, ethnicity, and number of BP medications (p= . 05). Trail 
Making Test-A and Symbol Digit Modalities Test were non-significant predictors of 
adherence in both adjusted and unadjusted analyses. cOnclusiOns: Trail Making 
Test-B, a measure of executive function, may be a useful screening tool to identify 
patients without overt dementia who are at risk for non-adherence to anti-hyper-
tensive medications. The findings from this study may provide an opportunity to 
identify a tailored approach to medication adherence interventions.
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Objectives: Hyperuricemia is an independent risk factor for gouty arthropathy, 
renal disease, atherosclerosis and cardiovascular diseases (CVD). The objective of 
this study was to explore the relationship between serum uric acid (SUA) levels and 
hospitalization events and assess health care costs. MethOds: A retrospective 
analysis using a large administrative database and a clinical registry containing 
laboratory results was performed. Subjects, aged ≥ 18, were assigned to one of 
the 4 groups based upon the first SUA measurement between October 1, 2010 and 
September 30, 2011: ≤ 6 mg/dl [good-control], > 6 mg/dl and ≤ 7 mg/dl [fair-control], 
> 7 mg/dl and ≤ 8 mg/dl [poor-control], > 8 mg/dl [very-poor-control]. We calculated 
incidence rates to estimate the risk of hyperuricemia-related and CVD hospitaliza-
tions occurred until December, 2012. A Poisson regression model was used to assess 
the relationship between the number of CVD hospitalizations and SUA level. Total 
annual costs included all the pharmacological treatments and the direct costs due 
to hospitalizations and outpatient services. Results: Of 52,822 patients included, 
SUA level was ≤ 6 mg/dl -good-control- for 33,638 (63.7%) patients and > 6 mg/dl 
–suboptimal-control- for 19,184 patients (36,3%), of whom 60,7% with fair-control, 
25,8% poor-control and 13,5% very-poor-control. Compared with good-control group, 
suboptimal-control patients showed an increased risk of hyperuricemia-related hos-
pitalizations (unadjusted rate was 1,02 vs 0,43 per 1000 person-years, p< 0.001) and 
of CVD hospitalizations (unadjusted rate 5,09 vs 3,17 per 100 person-years, p< 0.001; 
adjusted incidence rate ratio 1.22, p< 0.001). Over one year, the mean total cost was: 
€ 2,077.43 in good-control patients; € 2,079.87 in fair-control patients; € 2,296.39 in 
poor-control patients; € 3,295.41 in very-poor-control patients. cOnclusiOns: The 
36,3% of the patients in this study sample were at sub-optimal SUA control (> 6mg/dl). 
This analysis indicates that higher hyperuricemia-related and CVD hospitaliza-
tions as well as total health care costs resulted associated with higher SUA levels.
tified from the Clinical Practice Research Datalink (CPRD). From this cohort, three 
groups of patients were identified and counted for 2010, 2011 & 2012: Group 1 – 
very high-risk T2DM patients with CVD, TC ≥ 4.0 to < 5.0mmol/l and low-density 
lipoprotein cholesterol ≥ 2.0mmol/l despite statin treatment; Group 2 – untreated 
patients, with a TC ≥ 5.0mmol/l who were not prescribed any LLT after ceasing statin 
therapy; Group 3 – patients prescribed atorvastatin, rosuvastatin and/or ezetimibe 
with TC < 5.0mmol/l who previously had TC ≥ 5.0mmol/l. Numbers were extrapolated 
to the population in England. Results: Of the general population in England in 
2012, 8, 200, 699 (15.4%) patients had a TC test recorded, with similar proportions 
in 2010 & 2011 (15.4% and 15.3% respectively). Among the three groups defined in 
this analysis, a total of 305, 261 patients eligible for ezetimibe were not included 
in the 2012 estimates by HSCIC. This represents an 80.0% increase of the original 
estimate of 381, 797 patients using the original HSCIC methodology, corresponding 
to 33, 753, 141, 619, and 129, 889 patients in Groups 1, 2 and 3, respectively. Hence 
a year-on-year increase in the estimated eligible population were observed com-
pared to the original HSCIC estimate; 64.8% increase in 2010 and 75.7% increase in 
2011. cOnclusiOns: A significant and increasing number of high-risk patients 
eligible for ezetimibe were missed in the HSCIC estimates during 2010-2012.
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Objectives: describe the prevalence of venous thromboembolism (VTE), pul-
monary embolism (PE) and deep vein thrombosis (DVT) without PE among all 
hospitalized patients and the percentages of those occurring during the hospital 
stays. MethOds: Statistics are issued from the national PMSI MCO databases which 
are encoded using the CIM10. The codes used for VTE are I801 to I809 for DVT and 
codes I260, I269 for PE... Any stay with a the ICD-10 codes selected regardless of the 
Principal Diagnosis of Medical Unit Summaries and whatever its position (Principal, 
Related or Associated Diagnosis) was considered as a hospital-occurred thrombo-
sis unless it was the Principal Diagnosis of the first Medical Unit Summary of the 
stay. To eliminate outpatient consultations or in day care, stays of < 48 hours were 
excluded. The term of hospital-occurred is preferred to hospital-acquired VTE sug-
gesting a nosocomial origin which can be the case or not. Results: The results bear 
on the 18 683 603 hospital stays in 2010-2011. Out of 100 hospital stays involving VTE, 
for 40.3% VTE was the cause of hospitalization whereas 59.7% can be considered 
to have occurred during hospital-stay. These distributions are of 25.6% and 74.4% 
for DVT respectively 53.8% and 46.2% for PE. The age of patients varies little with 
whether VTE, DVT, and PE were hospital-occurred or not and are similar in men 
and women. The percentage of mortalities of these VTE is high and reaches 6.58% 
and the mortality from VTE, DVT, and PE is multiplied by a factor of 3 to 4 (p< . 0001) 
when hospital-occurred. cOnclusiOns: The high proportion of hospital-occurred 
VTE is an alarming situation that should question the quality of prevention and/or 
its effectiveness. VTE prevention policies must be strengthened in hospitals for the 
sake of patients and health care savings alike.
PCV25
risk FACtors AssoCiAted with Venous throMboeMbolisM reCurrenCe 
in A euroPeAn PoPulAtion
Hamilton M.1, Gupta S.2, Goren A.3, Auziere S.4, Claflin A.B.5, Reboul R.4, Phatak H.1
1Bristol-Myers Squibb Company, Princeton, NJ, USA, 2Kantar Health, Princeton, NJ, USA, 3Kantar 
Health, New York, NY, USA, 4Kantar Health, Montrouge, France, 5Pfizer, Inc., New York, NY, USA
Objectives: This study estimated venous thromboembolism (VTE) recurrence 
and associated risk factors in a European population, given limited data in this 
region. MethOds: This retrospective cohort study included data from physicians 
(376 general practitioners and 307 specialists) in France, Spain, Italy, and Germany, 
who completed case report forms (2,184 patient records) for the next 3-4 patients 
seen in consultation for any reason who had an initial VTE event 3 to 24 months 
prior (i.e., patients surviving 90 days since initial VTE). All Anderson & Spencer 
individual risk factors (plus gender, bleeding, and initial VTE type, but excluding 
previous VTE and bed rest > 3 days) were entered into a Cox proportional hazard 
model accounting for censored data and predicting VTE recurrence. Backward step-
wise regression was used to select a reduced final model. Results: Patients’ mean 
age was 61.3 years (SD= 14.3) and 47.4% were female. Of 2,184 patients, 379 devel-
oped recurrent VTE over 1,298 person-years of follow-up. The final model included: 
age= 40+ (91.6%) vs. 18-39 years, varicose veins (26.4%), history of heart failure (5.9%), 
congestive respiratory failure (1.3%), arthroscopic knee surgery (2.2%), central 
venous line (0.9%), chemotherapy (6.1%), and orthopedic (3.1%) surgery. Significant, 
independent predictors of recurrence were: varicose veins (hazard ratio [HR]: 1.4; 
95% confidence interval [CI] 1.1-1.8), central venous line (HR: 3.2; CI 1.5-6.8), con-
gestive respiratory failure (HR: 2.4; CI 1.2-4.6), and heart failure (HR: 1.5; CI 1.1-2.2). 
Other factors, including age= 40+, knee surgery, chemotherapy, orthopedic surgery, 
and type of VTE (e.g., deep vein thrombosis vs. pulmonary embolism) did not exhibit 
significant associations with recurrence of VTE. cOnclusiOns: VTE recurrence is 
high in this European population and associated with several independent risk fac-
tors. Targeted anticoagulant treatment post-initial VTE plus longer term prevention 
of recurrence are needed, including attention to risk factors that help differentiate 
patients more likely to experience recurrence.
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